Centocor Inc. (CNTO)
Cowen & Co. analyst Joyce Lonergan maintained a "neutral" rating and advised investors to wait to invest until the third quarter, when more information on ReoPro sales will be available. Interim data, due at the end of this month, also then will be available on the company's Capture trial in unstable angina. In